Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375535 | 0.78 | SLC9A1 (0.36) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL21888877 | 0.73 | KDM4E (0.34) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL19911638 | 0.72 | GRM2 (0.50) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL27249967 | 0.68 | PDE4A (0.37) | KDM4ETSHR | |
| SCHEMBL17422282 | 0.63 | SLC9A1 (0.34) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL19848287 | 0.63 | KEAP1 (0.47) | SLC9A1KEAP1KDM4E | |
| SCHEMBL16830895 | 0.62 | KDM4E (0.37) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL14921662 | 0.61 | KEAP1 (0.41) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL1965207 | 0.60 | SLC9A1 (0.48) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL23487160 | 0.59 | HSD17B10 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | SLC9A1 3052/4885KEAP1 1281/4885KDM4E 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.